Pages that link to "Q40694392"

The following pages link to Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis (Q40694392):

Displaying 27 items.

• Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma (Q37565108) (← links)
• Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. (Q38759920) (← links)
• Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy? (Q39187442) (← links)
• A review of the importance of immune responses in luminal B breast cancer. (Q39239484) (← links)
• The immune contexture in cancer prognosis and treatment (Q39456999) (← links)
• PD-L1 Expression and Combined Status of PD-L1/PD-1-Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients (Q41903951) (← links)
• Type Iγ phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF-κB. (Q41964740) (← links)
• Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer (Q47162071) (← links)
• Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis. (Q48307824) (← links)
• Posttranscriptional Control of PD-L1 Expression by 17β-Estradiol via PI3K/Akt Signaling Pathway in ERα-Positive Cancer Cell Lines (Q49214132) (← links)
• The Evolving Landscape of Brain Metastasis. (Q52673453) (← links)
• Albumin/globulin ratio is negatively correlated with PD-1 and CD25 mRNA levels in breast cancer patients. (Q55083652) (← links)
• Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. (Q55287222) (← links)
• Hypothesis: can the abscopal effect explain the impact of adjuvant radiotherapy on breast cancer mortality? (Q55304421) (← links)
• A panel containing PD-1, IL-2Rα, IL-10, and CA15-3 as a biomarker to discriminate breast cancer from benign breast disease. (Q55456412) (← links)
• Diagnostic value of PD-1 mRNA expression combined with breast ultrasound in breast cancer patients (Q58698521) (← links)
• Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases (Q90260599) (← links)
• Metastatic breast cancer cells induce altered microglial morphology and electrical excitability in vivo (Q90464645) (← links)
• Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond (Q90484961) (← links)
• Brain metastases (Q91099817) (← links)
• Immune Checkpoint Blockade - How Does It Work in Brain Metastases? (Q91866931) (← links)
• The role of the immune system in brain metastasis (Q92092437) (← links)
• Candidate genes and pathways associated with brain metastasis from lung cancer compared with lymph node metastasis (Q92298164) (← links)
• Tumor microenvironment differences between primary tumor and brain metastases (Q92405024) (← links)
• miR3609 sensitizes breast cancer cells to adriamycin by blocking the programmed death-ligand 1 immune checkpoint (Q92573084) (← links)
• Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis (Q96127666) (← links)
• Genomic landscape of the immune microenvironments of brain metastases in breast cancer (Q99635794) (← links)